Hereditary Leiomyomatosis and Renal Cell Carcinoma

Hereditary Leiomyomatosis and Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

8 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 3
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: Jonsson Comprehensive Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04981509	Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer	recruiting	Phase 2	65	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT01130519	A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer	completed	Phase 2	83	National Cancer Institute (NCI)NIH	1	Feb 21, 2025